SEC Form 4 · accession 0001209191-15-070228

Epizyme, Inc. · EPZM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Sep 8, 2015

Accepted (ET)

Sep 10, 2015 · 7:06 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001571498

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock, par value $0.0001 per share	Sep 8, 2015	M	60,000	$0.51	A	60,000	D
Common Stock, par value $0.0001 per share^F2	Sep 8, 2015	S	59,300	$19.8696	D	700	D
Common Stock, par value $0.0001 per share^F3	Sep 8, 2015	S	700	$19.25	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$0.51	Sep 8, 2015	M	60,000	D	—	Mar 17, 2020	Common Stock	60,000	387,223	D

F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.39 per share to $20.34 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.19 per share to $19.33 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4This option is fully vested.